AGIOS PHARMACEUTICALS

Agios Reports Business Highlights and Second Quarter 2021 Financial Results

29 Jul 2021 06:00:03 By Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Second Quarter 2021 Financial Results on July 29, 2021

15 Jul 2021 06:00:00 By Nasdaq GlobeNewswire

Agios Submits Marketing Authorisation Application to European Medicines Agency for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

28 Jun 2021 06:00:00 By Nasdaq GlobeNewswire

Agios Launches myAgios® Patient Support Services for Pyruvate Kinase Deficiency

22 Jun 2021 06:00:00 By Nasdaq GlobeNewswire

Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

21 Jun 2021 06:00:00 By Nasdaq GlobeNewswire

Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent α- and β-Thalassemia at the European Hematology Association Virtual Congress

11 Jun 2021 02:00:00 By Nasdaq GlobeNewswire

Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual Congress

11 Jun 2021 02:00:00 By Nasdaq GlobeNewswire

Agios to Present Updated Data from Clinical Trials of Mitapivat in Pyruvate Kinase Deficiency and Thalassemia in Oral Presentations at the European Hematology Association Annual Congress

12 May 2021 09:00:00 By Nasdaq GlobeNewswire

Agios Reports Business Highlights and First Quarter 2021 Financial Results

29 Apr 2021 06:00:01 By Nasdaq GlobeNewswire

Agios to Webcast Conference Call of First Quarter 2021 Financial Results on April 29, 2021

15 Apr 2021 06:00:00 By Nasdaq GlobeNewswire

Agios Announces Closing of Oncology Business Sale to Servier

01 Apr 2021 06:00:00 By Nasdaq GlobeNewswire

Agios Shareholders Approve Sale of Oncology Business to Servier

25 Mar 2021 15:01:00 By Nasdaq GlobeNewswire

Agios Sponsors Program Promoting Health Literacy for Patients with Sickle Cell Disease

18 Mar 2021 06:00:01 By Nasdaq GlobeNewswire

Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

01 Mar 2021 06:00:01 By Nasdaq GlobeNewswire

Agios Recognizes 14th Annual Rare Disease Day and Raises Awareness of Unmet Needs in Rare Hemolytic Anemias

26 Feb 2021 06:00:00 By Nasdaq GlobeNewswire

Agios Reports Fourth Quarter and Full Year 2020 Financial Results

25 Feb 2021 06:00:02 By Nasdaq GlobeNewswire

Agios to Present at March Investor Conferences

23 Feb 2021 06:00:01 By Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Fourth Quarter and Year End 2020 Financial Results on February 25, 2021

11 Feb 2021 06:00:01 By Nasdaq GlobeNewswire

Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused

26 Jan 2021 15:01:00 By Nasdaq GlobeNewswire

Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

17 Jan 2021 09:00:00 By Nasdaq GlobeNewswire